These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 29623110)

  • 1. Clinical assessment of immune-related adverse events.
    Sosa A; Lopez Cadena E; Simon Olive C; Karachaliou N; Rosell R
    Ther Adv Med Oncol; 2018; 10():1758835918764628. PubMed ID: 29623110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 checkpoint inhibition: Toxicities and management.
    Hahn AW; Gill DM; Agarwal N; Maughan BL
    Urol Oncol; 2017 Dec; 35(12):701-707. PubMed ID: 28889921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological Agents Used in Cancer Treatment.
    Simsek M; Tekin SB; Bilici M
    Eurasian J Med; 2019 Feb; 51(1):90-94. PubMed ID: 30911265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
    Ferrari SM; Fallahi P; Elia G; Ragusa F; Ruffilli I; Patrizio A; Galdiero MR; Baldini E; Ulisse S; Marone G; Antonelli A
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immune-related adverse events after immune checkpoints inhibitors in 2019: An update].
    Comont T; Belliere J; Sibaud V; Alric L; Meyer N; Mazières J; Caron P; Acket B; Michot JM; Beyne-Rauzy O; Lambotte O
    Rev Med Interne; 2020 Jan; 41(1):37-45. PubMed ID: 31668882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors.
    Kamińska-Winciorek G; Cybulska-Stopa B; Lugowska I; Ziobro M; Rutkowski P
    Postepy Dermatol Alergol; 2019 Aug; 36(4):382-391. PubMed ID: 31616210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
    Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
    Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.
    Vaddepally RK; Kharel P; Pandey R; Garje R; Chandra AB
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of Toxicities of Immune Checkpoint Inhibitors].
    Horio Y
    Gan To Kagaku Ryoho; 2017 Mar; 44(3):185-190. PubMed ID: 28292987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous adverse effects of the immune checkpoint inhibitors.
    Collins LK; Chapman MS; Carter JB; Samie FH
    Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity management of immunotherapy for patients with metastatic melanoma.
    Linardou H; Gogas H
    Ann Transl Med; 2016 Jul; 4(14):272. PubMed ID: 27563659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of destructive thyroiditis and diabetes mellitus after three injections of pembrolizumab for skin melanoma].
    Glibka AA; Mel Nichenko GA; Mikhina MS; Mazurina NV; Kharkevich GY
    Probl Endokrinol (Mosk); 2021 Feb; 67(2):20-27. PubMed ID: 34004100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.
    Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G
    Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.